NCT04506216 (Diaboulimia) is a NA clinical trial of cohort in Type 1 Diabetes, sponsored by Icadom.

Who is sponsoring NCT04506216?

NCT04506216 is sponsored by Icadom.

What drugs are being tested in NCT04506216?

Interventions in NCT04506216: cohort.

What condition does NCT04506216 study?

NCT04506216 studies Type 1 Diabetes, Eating Disorders.

Is NCT04506216 still recruiting?

NCT04506216 is currently completed. Last updated 8 April 2022.

Last reviewed 2022-04-08 · How we verify

NCT04506216: Diaboulimia

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eating Disorders in Type 1 Insulin-dependent Diabetes Patients

Completed NA Last updated 8 April 2022

What this trial tests

NA trial testing cohort in Type 1 Diabetes in 200 participants. Completed in 23 December 2021.

Timeline

1 September 2020

Primary endpoint
23 December 2021

23 December 2021

Quick facts

Lead sponsor	Icadom
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	200
Start date	1 September 2020
Primary completion	23 December 2021
Estimated completion	23 December 2021
Sites	1 location across France

Drugs / interventions tested

cohort

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →
Eating Disorders — all drugs for Eating Disorders →

Sponsor

Icadom — full company profile →

Who can join

18 and older, any sex, with Type 1 Diabetes or Eating Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of cohort

Trials testing the same drug.

NCT05852678 — A Population-based Cohort in Northern Spain · recruiting

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Icadom trials

Trials by the same sponsor.

NCT03130361 — Wearable Noninvasive Positive Pressure Ventilation Device in COPD · NA · completed
NCT02791295 — Lifestyle Intervention in Type 2 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04506216 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icadom
Last refreshed: 8 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04506216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing